Four patients with AL amyloidosis underwent high-dose chemotherapy and autologous stem cell transplantation at our institutions. Here, we report the clinical courses and outcomes in these patients. Two patients with multiorgan amyloid deposits including cardiac involvement died within 12 days after high-dose chemotherapy. However, in the other two patients, one of whom was suffering from amyloid-related cardiac failure, a significant improvement of organ function was achieved. Bone Marrow Transplantation (2001) 27, 341-343.
Patients with amyloid light chain (AL) amyloidosis have a very poor prognosis with a median survival of 13 months from diagnosis. 1 If cardiac involvement with progressive reduction of left ventricular ejection fraction is documented, the median survival is reduced to 5 months. 2 The majority of patients succumb to cardiorespiratory failure, renal failure and/or vascular bleeding.
Response to cytostatic treatment with alkylating agents, supplemented by glucocorticoids and/or colchicine, are minimally effective. 2 Recently, high-dose chemotherapy with haematopoietic stem cell support has been introduced in the treatment of patients with AL amyloidosis in order to improve organ function and prolong survival. [3] [4] [5] We report the clinical courses and outcomes in four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. 
Case reports

Patient 1
A 41-year-old woman was hospitalized for rapidly progressive ankle oedema due to nephrotic syndrome. Twentyfour hour proteinuria was 6.5 g, and creatinine clearance was normal. Serum cholesterol was 7.46 mmol/l and serum albumin 24 g/l. AL amyloidosis was proven on renal biopsy. Monoclonal lambda light chains were detected in the urine by immune-fixation. Further investigation showed no other organ involvement. Haematopoietic progenitor cells were mobilised from G-CSF (10 g/kg/day for 4 days), and 4.1 × 10 6 CD34-positive cells per kg were harvested by leucapheresis. In November 1997, the patient underwent high-dose chemotherapy with melphalan 200 mg/m 2 followed by autologous stem cell transplantation (ASCT). Duration of severe neutropenia, defined as granulocyte counts Ͻ0.5 × 10 9 /l, was 4 days with no infectious complications. No platelet support was required. Nonhaematological toxicity consisted of grade III mucositis treated with analgesics.
At 19 months post transplant, the patient is free from disease-specific symptoms. The twenty-four hour proteinuria has reduced to 1 g and immune-fixation on urine and plasma is negative. Serum albumin is 42 g/l, and the cholesterol level 7.07 mmol/l. Renal sonography shows no pathological findings and no further organ involvement has observed.
Patient 2
A 60-year-old man was admitted in December 1997 for progressive dyspnoea (New York Heart Association grade 2) and ankle oedema. From April 1997 atrial fibrillation had been documented. Echocardiography showed the left ventricular ejection fraction (LVEF) to be reduced to 34%. Interventricular septum thickness was 15 mm. Twenty-four hour proteinuria was 8 g, and creatinine clearance was normal. Plasma immune fixation was positive for lambda light chains. Biopsies of the rectal mucosa, liver and heart showed unequivocal involvement by AL amyloidoses. From December 1997 to February 1998, the patient received two cycles of chemotherapy consisting of conventional-dose melphalan (16 mg/m 2 day 1) and prednisolone 2 Because of non-response and deterioration of clinical symptoms, highdose chemotherapy was scheduled. Progenitor cells were mobilised by G-CSF as described above, and 2.9 × 10 6 CD34-positive cells per kg were harvested by leukapheresis. In February 1998, the patient underwent chemotherapy with melphalan 200 mg/m 2 followed by ASCT. On day +8 post transplant empiric antimicrobial therapy was started for unexplained fever. Severe neutropenia was present from day +4, and a platelet transfusion was given on day +8. On day +10, rapidly progressive cardiorespiratory failure necessitated mechanical ventilation and i.v. pressor support. Cardiac arrest caused by electromechanical dissociation refractory to resuscitation caused death on day +12 post transplant. Autopsy revealed acute myocardial infarction as the main cause of death.
Patient 3
A 61-year-old man was hospitalized in December 1998 because of hypotension, diarrhoea and paraesthesia of the hands and feet. He was unable to continue working as a teacher. Subcutaneus fat aspiration and biopsy of the rectal mucosa both revealed AL amyloidosis. Plasma immune fixation was negative. Bone marrow biopsy showed perivascular amyloid deposits and expression of lambda light chains. Echocardiography and cardiac magnetic resonance imaging (MRI) showed the typical findings of cardiac amyloidosis with reduction in systolic function. 6 LVEF was reduced to 40%, and the interventricular septum thickness was 21 mm. The creatinine clearance was normal, and pathological urine protein excretion was not observed. Progenitor cells were mobilised by G-CSF as described above, and 2.2 × 10 6 CD34-positive cells per kg were harvested. In February 1999, the patient underwent chemotherapy with melphalan 140 mg/m 2 followed by ASCT. Duration of severe neutropenia was 6 days, severe thrombocytopenia was not observed, and no transfusion of blood products was required. An episode of unexplained fever during neutropenia promptly responded to first-line antibiotic treatment. Non-haematological toxicity was limited to grade III mucositis. At 7 months post transplant, the patient's blood pressure has normalised, echocardiography and cardiac MRI show no signs of cardiac involvement and LVEF has returned to normal. The patient continues to suffer from stable paresthesia and diarrhoea, but he has returned to work.
Patient 4
A 61-year-old man was hospitalized in December 1997 because of ankle oedema due to nephrotic sydrome, with a 24 h proteinuria of 16 g. Monoclonal lambda light chains were detected in urine and serum by immune fixation. Creatinine clearance was normal. He suffered from dyspnoea NYHA 2 and hypotension. Renal, liver and bone marrow histology revealed disseminated AL amyloidosis. Echocardiography and cardiac MRI showed typical features of cardiac amyloidosis with a normal LVEF and impaired diastolic relaxation. Chest radiography was suspicious of pulmonary involvement. However, the carbon monoxide (CO) diffusion capacity was normal. Two cycles of G-CSF, each given as described above, were required to achieve a yield of 2.26 × 10 6 CD34-positive cells per kg from steady state. In February 1998, the patient received chemotherapy with melphalan 200 mg/m 2 followed by ASCT. Two days after the chemotherapy the patient developed haematemesis. Prompt endoscopy of the upper gastrointestinal tract revealed no bleeding source. On the day of ASCT haemoptysis occurred. Within 4 h the patient rapidly developed respiratory failure caused by diffuse alveolar haemorrhage requiring mechanical ventilation. Adequate oxygenation was not achievable despite ventilation, and the patient expired. Autopsy showed significant lung involvement by amyloidosis resulting in diffuse alveolar bleeding and right ventricular cardiac failure.
Discussion
This report confirms that high-dose chemotherapy with autologous stem cell support offers a feasible and effective strategy for patients with advanced AL amyloidosis. However, patients with multi-organ involvement, including cardiac amyloidosis, are at very high risk of treatment-related toxic death. Therefore, their exclusion from this treatment modality is recommended by some authors. 5, 7, 8 This recommendation causes a therapeutic dilemma, since these patients have a median survival of 5 months when treated with conventional-dose melphalan with prednisone. 2 In their preliminary report, Comenzo et al 4 described 102 patients with AL amyloidosis and a median age of 61 years treated with high-dose chemotherapy consisting of melphalan 100 or 200 mg/m 2 in a randomized trial. With a median follow-up of 20 months, 70% of patients in the high-dose melphalan group and 63% in the intermediatedose melphalan group survived. Patients with cardiac involvement and LVEF reduced to less than 50%, renal failure or pulmonary CO diffusion capacity of less than 50% underwent intermediate-dose melphalan therapy. Again, 20% of patients died within 100 days post treatment, and all these patients suffered from cardiac involvement, or had more than two organ systems affected by amyloidosis. When presenting his outcome analysis of high-dose melphalan and stem cell support in patients with vs those without cardiac involvement, Comenzo 9 showed a 3-year overall survival of 25% in 18 patients with cardiac amyloidosis.
Saba et al 10 published their observations on 11 patients with AL amyloidosis and cardiac involvement, nine of whom were eligible for high-dose chemotherapy. Three patients died from fatal cardiac arrhytmia or heart failure after mobilisation with cyclophosphamide at a dose of 2.5 g/m 2 plus G-CSF. During or shortly after high-dose chemotherapy with melphalan 140 mg/m 2 and total body irradiation, three further patients died from cardiac complications. The remaining three patients also developed arrhythmias during neutropenia, but two of them achieved improved organ function documented after therapy, resulting in a favourable treatment outcome in two of nine (22%) patients. Moreau et al 5 studied the safety and feasibility of high-dose chemotherapy followed by ASCT in 21 patients with systemic AL amyloidosis. The fatality rate due to toxicity within the first month post-transplant was high, at 43%. Overall survival at 4 years was 57% for all study patients and 11% for those with more than two clinical manifestations such as renal failure, nephrotic syndrome, congestive heart failure, neuropathy or hepatomegaly. As a consequence, they recommended restricting stem cell mobilisation, high-dose therapy and stem cell support to patients without multiple-organ involvement by AL amyloidosis.
It may be interesting to analyse the impact of AL light chain amyloidosis in patients with multiple myeloma undergoing aggressive chemoradiotherapy with repeated high-dose melphalan, total body irradiation and autologous stem cell transplantation. Reviewing their data on the outcome of 'total therapy' in patients with multiple myeloma, Desikan et al 11 found no significant differences between patients with (38%) or without (62%) amyloidosis documented by routine subcutaneous fat pad aspirates or organdirected biopsies in a series of 84 myeloma patients.
We conclude that high-dose chemotherapy may be effective in patients with AL amyloidosis, but that in patients with cardiac involvement or involvement of more than two organ systems, a high rate of treatment-related complications must be anticipated. At the same time, it must be emphasized that patients with congestive heart failure caused by AL amyloidosis have a considerably poorer median survival with only minimal benefit from conventional chemotherapy with melphalan and prednisone. 2 To date, the best therapy for patients with cardiac involvement has not been determined. In one patient (No. 3) in our report, the potential benefit from high-dose chemotherapy, as shown by significant improvement of cardiac function, is clearly demonstrated. Although very preliminary, this observation corresponds well to the other reports cited showing survival rates of approximately 20-25% in this high-risk subgroup of AL amyloidosis patients. Organ improvement in case of cardiac amyloidosis is rarely reported. 12 Therefore, in most patients with only one organ system affected by AL amyloidosis, high-dose chemotherapy may be safe and effective, whereas just those patients with multi-organ involvement, in whom an improvement of treatment options is urgently required, must be regarded as a high-risk group with respect to treatment-related mortality. Because of the high treatmentrelated mortality, we consider that there is no role for solid organ transplantation in cases of advanced cardiac or liver amyloidosis prior to high-dose chemotherapy until more clinical experience is available.
